ASX Linkedin Twitter               

 

Analyst Coverage 2015

Bioshares Edition 630
18 December 2015
2016 Top Six Stock Picks: Viralytics – A Competitive Therapy

Edison
27 November 2015
Combination Trials Gather Momentum

Bioshares Edition 625
13 November 2015
Viralytics Collaborates with Merck to Make the Best Even Better

Bell Potter
9 November 2015
Merck Collaboration Validates Strategy

Roth Capital Partners
6 November 2015
Positive Change to STORM Direction; Merck Collaborating

Bioshares Edition 623
30 October 2015
Approval Of Amgen’s T-Vec Opens Door For Viralytics’ CAVATAK

Roth Capital Partners
28 October 2015
Regulatory Door Wide Open Now for Differentiated CAVATAK

Bell Potter
7 October 2015
Extension study confirms Immune System Upregulation

Roth Capital Partners
28 September 2015
CALM Extension Data and New Combo Study; Reiterate Buy

Roth Capital Partners
28 August 2015
FY15 Results; T-Vec PDUFA & Upcoming Data Should Boost Visibility

Edison
13 August 2015
Clinical Data Pack Continues to Build

Bell Potter
20 July 2015
Viralytics – an immuno-oncology play

Roth Capital Partners
20 July 2015
Another Shot Across the Talimogene Bow; STORM Increments

Bioshares Edition 605
22 June 2015
CAVATAK Tested in Three Routes of Administration

Roth Capital Partners
16 June 2015
CAVATAK Profile Continues to Grow

Bioshares Edition 603
5 June 2015
Viralytics Achieves 21% Durable Response with CAVATAK

Roth Capital Partners
2 June 2015
Flash Note – Amgen Doing the Heavy Lifting but VLA Can Be Beneficiary

Roth Capital Partners
2 June 2015
We’re CALM Yet Excited

Bell Potter
2 June 2015
CALM Delivers

Bioshares Edition 598
4 May 2015
FDA Advisory Vote on Amgen’s T-Vec a Positive for Viralytics

Edison
30 April 2015
STORM shows promise at AACR

ROTH Capital Partners
30 April 2015
T-Vec FDA ODAC Approval – Big Boost for Oncolytic Viruses; See CAVATAK Differentiation

Bell Potter
29 April 2015
T-Vec Lights the way for Oncolytic Virotherapy

BBY
28 April 2015
Encouraging Results from Clinical Trials

Bioshares Edition 597
24 April 2015
Viralytics Builds Data Pack for Partners

Roth Capital Partners
20 April 2015
Viralytics Update – CALM and STORM Updates Mix Well Together

Roth Capital Partners
14 April 2015
Viralytics Update – Upcoming T-Vec FDA Advisory Committee Should Boost Visibility

Bioshares Edition 590
6 March 2015
US Investors take note of Viralytics

Roth Capital Partners
25 February 2015
Initiation of Coverage – “One-Two Punch to Killing Cancer”

Bioshares Edition 586
6 February 2015
Viralytics Briefing Report

Edison
8 January 2015
Building the Data Package

Viralytics Limited
Suite 305, Level 3, 66 Hunter Street
Sydney NSW 2000 Australia
T: +61 (0)2 9988 4000 F: +61 (0)2 8068 6038

© Viralytics Limited 2017
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).